An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer
Abstract Background Anti-androgen resistance remains a major clinical challenge in the treatment of prostate cancer (PCa), leading to disease progression and treatment failure. Despite extensive research on resistance mechanisms, a reliable prognostic model for predicting patient outcomes and guidin...
Saved in:
| Main Authors: | Ruilin Zhuang, Ruihui Xie, Shirong Peng, Qianghua Zhou, Weilong Lin, Yuan Ou, Bingliang Chen, Tong Su, Zean Li, Hai Huang, Kaiwen Li, Yu Duan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06457-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer
by: Fu-Hao Ji, et al.
Published: (2025-08-01) -
Precision targeting of androgen receptor–ferroptosis crosstalk in prostate cancer: From mechanisms to therapeutic strategies
by: Dongfang Lv, et al.
Published: (2025-09-01) -
DRUG THERAPY FOR ANDROGEN-POSITIVE BREAST CANCER
by: A. D. Zikiryakhodjhaev, et al.
Published: (2021-03-01) -
Complete Androgen Insensitivity Syndrome: Role of Imaging for Diagnosis
by: Ravina Ravina, et al.
Published: (2025-04-01) -
Immunometabolism signature derived from on-treatment tumor specimens predicts immune checkpoint blockade response in metastatic melanoma
by: Shuzhao Chen, et al.
Published: (2025-07-01)